Skip to main content

Table 3 Potential biomarkers in feces associated with AEE treatment based on UPLC-Q-TOF/MS analysis in hyperlipidemic rat

From: Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats

NO. RT VIP m/z Formula Metabolite Trend
M/C AEE/M
1 6.8 6.04 391.2835 C24H38O4 Nutriacholic acid
2 6.92 2.82 318.2996 C18H39NO3 Phytosphingosine *
3 7.53 4.67 300.2892 C18H37NO2 Sphingosine *
4 10.19 4.80 281.2468 C18H32O2 Linoleic acid **
5 13.25 3.27 428.3733 C25H49NO4 Stearoylcarnitine **
6 1.74 1.71 132.1011 C6H13NO2 Leucine *
7 3.55 1.77 161.1061 C10H12N2 Tryptamine
8 7.54 2.20 282.2788 C18H35NO Oleamide *
9 0.67 1.51 145.1211 C8H16O2 Caprylic acid **
10 6.76 1.43 298.2731 C18H35NO2 POEA
11 11.15 1.63 279.2312 C16H32O2 Palmitic acid **
12 16.55 1.52 328.3206 C20H41NO2 Stearoylethanolamide
13 12.03 1.17 357.2785 C24H36O2 THA ** *
14 3.73 1.45 206.0449 C10H9NO4 4-(2-A)-2,4-DA *
15 4.36 1.74 165.0550 C9H10O3 Phenyllactic acid ** *
16 5.41 2.25 297.1122 C18H18O4 Enterolactone **
17 11.5 4.69 299.2580 C18H36O3 13-HA **
18 13.23 1.51 277.2163 C18H30O2 Alpha-Linolenic acid **
19 16.43 2.75 281.2475 C18H34O2 Oleic acid **
20 4.04 1.23 229.1435 C12H22O4 Dodecanedioic acid **
21 7.68 1.05 389.2685 C24H38O4 12-Ketodeoxycholic acid
22 13.87 1.24 327.232 C22H32O2 DHA **
  1. M/C: model versus control; AEE/M: AEE versus model; * P < 0.05, ** P < 0.01. POEA: Palmitoleoyl ethanolamide; THA: Tetracosahexaenoic acid; 4-(2-A)-2,4-DA: 4-(2-Aminophenyl)-2,4-dioxobutanoic acid; DHA: Docosahexaenoic acid; 13-HA: 13-hydroxyoctadecanoic acid